RayKnowChina Research Map
Shortlist0

TaizhouWenzhou Medical University

Taizhou Hospital, Wenzhou Medical University

温州医科大学附属台州医院

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Taizhou Hospital, Wenzhou Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌11 papers led
  3. Hepatocellular carcinoma肝细胞癌27 papers led
  4. Stomach cancer胃癌17 papers led
  5. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  6. Multiple myeloma多发性骨髓瘤2 papers led
  7. Beta thalassaemiaβ 地中海贫血1 paper led
  8. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  9. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病0 papers led
  10. Fabry disease法布雷病0 papers led
  11. Behçet disease白塞病0 papers led
  12. Alport syndromeAlport 综合征1 paper led
  13. IgA nephropathyIgA 肾病0 papers led
  14. Osteogenesis imperfecta成骨不全症0 papers led
  15. Primary biliary cholangitis原发性胆汁性胆管炎1 paper led

Not listed for: Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 2220242025: 002025

3 hospitals in Taizhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueSide effects & quality of lifeRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryRadiation oncologyGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 11 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
11
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 5520242025: 222025

1 hospital in Taizhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06342167

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesAnyang, Fuzhou, Taizhou, Tianjin, Xinxiang, Yinchuan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentRadiotherapyEarly detection & endoscopy
Departments in papersGastroenterology / hepatologyRadiation oncologySurgery (general/hepatobiliary/pancreatic)

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led11
  1. Artificial intelligence in early screening for esophageal squamous cell carcinoma.2025Best practice & research. Clinical gastroenterology
  2. SLC39A14 promotes the development of esophageal squamous cell carcinoma through PI3K/Akt/mTOR signaling pathway.2025International immunopharmacology
  3. IKBIP promotes tumor development via the akt signaling pathway in esophageal squamous cell carcinoma.2024BMC cancerFree full text
  4. CDKL3 shapes immunosuppressive tumor microenvironment and initiates autophagy in esophageal cancer.2024Frontiers in immunologyFree full text
  5. Overexpression of ZNF468 promotes esophageal squamous cell carcinoma progression via the AKT/mTOR pathway.2024International immunopharmacology
  6. Cardiac substructures dosimetric predicts cardiac toxicity and prognosis in esophageal squamous cell cancer treated by radiotherapy.2024Neoplasia (New York, N.Y.)Free full text
  7. Deep learning assists detection of esophageal cancer and precursor lesions in a prospective, randomized controlled study.2024Science translational medicineRCT
  8. PD-1/PD-L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta-analysis focus on PD-L1 expression level.2023Cancer reports (Hoboken, N.J.)Free full text
  9. Prognostic value of recurrence pattern in locally advanced esophageal squamous cell carcinoma: Results from the phase III trial NEOCRTEC5010.2023The Journal of thoracic and cardiovascular surgeryRCT
  10. (Neo)adjuvant Chemoradiotherapy is Beneficial to the Long-term Survival of Locally Advanced Esophageal Squamous Cell Carcinoma: A Network Meta-analysis.2022World journal of surgery
  11. Lesion human leukocyte antigen-E is associated with favourable prognosis for patients with oesophageal squamous cell carcinoma.2021The Journal of international medical researchFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal CancerStatus unknownNCT02188615Lead (inferred)Phase 2Start 2011-06
  2. Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell CarcinomaRecruitingNCT06342167Study sitePhase 2Start 2024-03
  3. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 27 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 8820232024: 8820242025: 662025

1 hospital in Taizhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  2. Not yet recruiting
    Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07596134

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Nanchang, Taizhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineRadiation oncologyGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led27
  1. Digital pathology-based prognostic model for hepatocellular carcinoma: Integrating pathomics signatures with clinical parameters for recurrence prediction and biological interpretation.2026Computer methods and programs in biomedicine
  2. Radiomics Model of Dynamic Contrast-Enhanced MRI for Evaluating Vessels Encapsulating Tumor Clusters and Microvascular Invasion in Hepatocellular Carcinoma.2025Academic radiology
  3. The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review.2025BMC cancerFree full text
  4. NEIL3 Upregulated by TFAP2A Promotes M2 Polarization of Macrophages in Liver Cancer via the Mediation of Glutamine Metabolism.2025Digestion
  5. No-touch ablation for hepatocellular carcinoma: a narrative review.2025International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  6. Prognostic significance of pyrimidine metabolism-related genes as risk biomarkers in hepatocellular carcinoma.2025Journal of chemotherapy (Florence, Italy)
  7. A meta-analytic and systematic review to compare perioperative outcomes and prognosis between robotic and conventional (laparoscopic or open) liver resection in hepatocellular carcinoma cases.2025World journal of surgical oncologyFree full text
  8. A deep learning model based on MRI for prediction of vessels encapsulating tumour clusters and prognosis in hepatocellular carcinoma.2024Abdominal radiology (New York)
  9. High expression of circulating exosomal PD-L1 contributes to immune escape of hepatocellular carcinoma and immune clearance of chronic hepatitis B.2024AgingFree full text
  10. The m6A methyltransferase METTL5 promotes neutrophil extracellular trap network release to regulate hepatocellular carcinoma progression.2024Cancer medicineFree full text
  11. Transcription Factor MAZ Potentiates the Upregulated NEIL3-mediated Aerobic Glycolysis, thereby Promoting Angiogenesis in Hepatocellular Carcinoma.2024Current cancer drug targets
  12. A nomogram model for early recurrence of HBV-related hepatocellular carcinomas after radical hepatectomy.2024Frontiers in endocrinologyFree full text
  13. Role of immune related genes in predicting prognosis and immune response in patients with hepatocellular carcinoma.2024Journal of biochemical and molecular toxicology
  14. Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma.2024Oncology researchFree full text
  15. Comparison of liver resection and radiofrequency ablation in long-term survival among patients with early-stage hepatocellular carcinoma: a meta-analysis of randomized trials and high-quality propensity score-matched studies.2024World journal of surgical oncologyFree full text
  16. Preoperative MRI features for characterization of vessels encapsulating tumor clusters and microvascular invasion in hepatocellular carcinoma.2023Abdominal radiology (New York)
  17. Comprehensive analysis of UBE2C expression and its potential roles and mechanisms in hepatocellular carcinoma.2023AgingFree full text
  18. Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.2023Applied biochemistry and biotechnologyFree full text
  19. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.2023Clinics and research in hepatology and gastroenterology
  20. SNHG3 regulates NEIL3 via transcription factor E2F1 to mediate malignant proliferation of hepatocellular carcinoma.2023Immunogenetics
  21. Effect of intermittent Pringle maneuver on perioperative outcomes and long-term survival following liver resection in patients with hepatocellular carcinoma: a meta-analysis and systemic review.2023World journal of surgical oncologyFree full text
  22. Efficacy of transarterial therapy combined with first-line tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a network meta-analysis.2023World journal of surgical oncologyFree full text
  23. Does adjuvant hepatic artery infusion chemotherapy improve patient outcomes for hepatocellular carcinoma following liver resection? A meta-analysis.2023World journal of surgical oncologyFree full text
  24. Long-Term Survival and Risk Factors in Patients with Hepatitis B-Related Hepatocellular Carcinoma: A Real-World Study.2022Canadian journal of gastroenterology & hepatologyFree full text
  25. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.2022International immunopharmacology
  26. MRI-Based Radiomics: Nomograms predicting the short-term response after transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma patients with diameter less than 5 cm.2021Abdominal radiology (New York)
  27. Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma.2021AgingFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Study siteN/AStart 2026-10
  2. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 17 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 7720222023: 2220232024: 1120242025: 662025

1 hospital in Taizhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  2. Recruiting
    Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese Patients
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07175155

    Age 18 years to Not stated (registered criteria)

    Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesBeijing, Hangzhou, Taizhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIEarly detection & endoscopySurgery
Departments in papersGastroenterology / hepatologyMedical oncologyRadiation oncologySurgery (general/hepatobiliary/pancreatic)

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led17
  1. Association between calcification and risk stratification in gastric gastrointestinal stromal tumors.2025Abdominal radiology (New York)
  2. Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B.2025BMC cancerFree full text
  3. Prognostic risk stratification value of MACC1 expression in patients with gastric cancer.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. Predicting clinical prognosis in gastric cancer using deep learning-based analysis of tissue pathomics images.2025Computer methods and programs in biomedicine
  5. HLA-G expression in peritumoral fundic gland mucous neck cells, but not in tumor lesions, related to poor survival in patients with gastric cancer.2025Frontiers in immunologyFree full text
  6. Glucokinase Regulatory Protein (GCKR) Links Metabolic Reprogramming With Immune Exclusion: Insights From a Pan-Cancer Analysis and Gastric Cancer Validation.2025Human mutationFree full text
  7. Prognostic impact of a 3-week multimodal prehabilitation program on frail elderly patients undergoing elective gastric cancer surgery: a randomized trial.2024BMC gastroenterologyRCTFree full text
  8. Development and validation of LightGBM algorithm for optimizing of Helicobacter pylori antibody during the minimum living guarantee crowd based gastric cancer screening program in Taizhou, China.2023Preventive medicine
  9. Nomogram for predicting survival of patients with gastric cancer and multiple primary malignancies: a real-world retrospective analysis using the Surveillance, Epidemiology and End Results database.2023The Journal of international medical researchFree full text
  10. MiR-1-3p targets CENPF to repress tumor-relevant functions of gastric cancer cells.2022BMC gastroenterologyFree full text
  11. Circ-DONSON Facilitates the Malignant Progression of Gastric Cancer Depending on the Regulation of miR-149-5p/LDHA Axis.2022Biochemical genetics
  12. LINC00839 Promotes the Progression of Gastric Cancer by Sponging miR-1236-3p.2022Bulletin of experimental biology and medicine
  13. Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy.2022Computational and mathematical methods in medicineFree full text
  14. Targeting AURKA by microRNA-490-3p suppresses gastric cancer cell growth.2022Histology and histopathology
  15. Pre-operative neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with gastric cancer.2022International immunopharmacology
  16. Prognostic significance of the immune checkpoint HLA-G/ILT-4 in the survival of patients with gastric cancer.2022International immunopharmacology
  17. Endoscopic resection of large (≥ 4 cm) upper gastrointestinal subepithelial tumors originating from the muscularis propria layer: a single-center study of 101 cases (with video).2021Surgical endoscopy
All its trials on ClinicalTrials.gov, any status10
  1. Effects of Multimodal Prehabilitation on Frail Elderly Patients Undergoing Elective Gastric Cancer SurgeryCompletedNCT06510088Lead sponsorN/AStart 2019-03
  2. Combination of COMBO Endoscopy Oropharyngeal Airway and HFNC Oxygenation in Sedated Gastrointestinal Endoscopy for Morbidly Obese PatientsRecruitingNCT07175155Study siteN/AStart 2025-10
  3. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  4. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  5. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  6. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  7. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Study sitePhase 1Start 2021-03
  8. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  9. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  10. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Taizhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Taizhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-08
    Registry
    NCT06520176

    Age 18 years to 75 years (registered criteria)

    Led by Affiliated People's Hospital of Ningbo University; 6 listed hospitals as study sitesHangzhou, Ningbo, Taizhou, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskKidney & bone complications
Departments in papersPathology / laboratory medicine

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Taizhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. De novo HBB frameshift mutation in a patient with dominant β-thalassemia major.2022International journal of laboratory hematology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Taizhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Anti-NMDA receptor encephalitis following SARS-CoV-2 infection in children.2025Diagnostic microbiology and infectious disease

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led no English-language PubMed papers on lymphangioleiomyomatosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Taizhou for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led no English-language PubMed papers on Fabry disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taizhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [A case of Fabry disease misdiagnosed for 30 years].2024Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taizhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Chinese-language papers (not in the count)1
  1. [Pathogenesis and treatment progression of myelodysplastic syndrome combined with Behçet's syndrome].2025Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Taizhou for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineNephrology

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Taizhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Taizhou for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 1 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Taizhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Developing a Prognostic Model for Primary Biliary Cholangitis Based on a Random Survival Forest Model.2024International journal of medical sciences
All its trials on ClinicalTrials.gov, any status1
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

温州医科大学附属台州医院

Taizhou Hospital, Wenzhou Medical University

台州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data